Pharma Companies Get On Board With Regeneron To Speed Biobank Sequencing

AbbVie, Alnylam, AstraZeneca and Pfizer join forces with Regeneron to speed up the sequencing of the 500,000 genetic samples in the UK's Biobank.

Conductor
All aboard the sequencing train • Source: Shutterstock

An initiative to sequence genetic samples from 500,000 participants in the UK's Biobank by Regeneron Pharmaceuticals Inc. has received a boost with new funding from four pharma companies, which should speed the completion of the work by nearly three years.

The "pre-competitive" consortium will see AbbVie Inc., Alnylam Pharmaceuticals Inc., AstraZeneca PLC and Pfizer Inc. each...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from R&D

More from Scrip